315 related articles for article (PubMed ID: 38339398)
1. Cuproptosis: Unraveling the Mechanisms of Copper-Induced Cell Death and Its Implication in Cancer Therapy.
Springer C; Humayun D; Skouta R
Cancers (Basel); 2024 Feb; 16(3):. PubMed ID: 38339398
[TBL] [Abstract][Full Text] [Related]
2. Ferroptosis inducers enhanced cuproptosis induced by copper ionophores in primary liver cancer.
Wang W; Lu K; Jiang X; Wei Q; Zhu L; Wang X; Jin H; Feng L
J Exp Clin Cancer Res; 2023 Jun; 42(1):142. PubMed ID: 37277863
[TBL] [Abstract][Full Text] [Related]
3. Regulatory roles of copper metabolism and cuproptosis in human cancers.
Wang Z; Jin D; Zhou S; Dong N; Ji Y; An P; Wang J; Luo Y; Luo J
Front Oncol; 2023; 13():1123420. PubMed ID: 37035162
[TBL] [Abstract][Full Text] [Related]
4. Copper's dual role: unravelling the link between copper homeostasis, cuproptosis, and cardiovascular diseases.
Parsanathan R
Hypertens Res; 2024 May; 47(5):1440-1442. PubMed ID: 38467792
[TBL] [Abstract][Full Text] [Related]
5. Novel insights into anticancer mechanisms of elesclomol: More than a prooxidant drug.
Gao J; Wu X; Huang S; Zhao Z; He W; Song M
Redox Biol; 2023 Nov; 67():102891. PubMed ID: 37734229
[TBL] [Abstract][Full Text] [Related]
6. Elesclomol: a copper ionophore targeting mitochondrial metabolism for cancer therapy.
Zheng P; Zhou C; Lu L; Liu B; Ding Y
J Exp Clin Cancer Res; 2022 Sep; 41(1):271. PubMed ID: 36089608
[TBL] [Abstract][Full Text] [Related]
7. Cuproptosis: A novel therapeutic target for overcoming cancer drug resistance.
Wang Y; Chen Y; Zhang J; Yang Y; Fleishman JS; Wang Y; Wang J; Chen J; Li Y; Wang H
Drug Resist Updat; 2024 Jan; 72():101018. PubMed ID: 37979442
[TBL] [Abstract][Full Text] [Related]
8. Cope with copper: From molecular mechanisms of cuproptosis to copper-related kidney diseases.
Zou Y; Wu S; Xu X; Tan X; Yang S; Chen T; Zhang J; Li S; Li W; Wang F
Int Immunopharmacol; 2024 May; 133():112075. PubMed ID: 38663316
[TBL] [Abstract][Full Text] [Related]
9. Copper metabolism and cuproptosis in human malignancies: Unraveling the complex interplay for therapeutic insights.
Abdullah KM; Kaushal JB; Takkar S; Sharma G; Alsafwani ZW; Pothuraju R; Batra SK; Siddiqui JA
Heliyon; 2024 Mar; 10(5):e27496. PubMed ID: 38486750
[TBL] [Abstract][Full Text] [Related]
10. Exploring cuproptosis as a mechanism and potential intervention target in cardiovascular diseases.
Yang Y; Feng Q; Luan Y; Liu H; Jiao Y; Hao H; Yu B; Luan Y; Ren K
Front Pharmacol; 2023; 14():1229297. PubMed ID: 37637426
[TBL] [Abstract][Full Text] [Related]
11. ATF3/SPI1/SLC31A1 Signaling Promotes Cuproptosis Induced by Advanced Glycosylation End Products in Diabetic Myocardial Injury.
Huo S; Wang Q; Shi W; Peng L; Jiang Y; Zhu M; Guo J; Peng D; Wang M; Men L; Huang B; Lv J; Lin L
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675183
[TBL] [Abstract][Full Text] [Related]
12. Cuproptosis: unveiling a new frontier in cancer biology and therapeutics.
Feng Y; Yang Z; Wang J; Zhao H
Cell Commun Signal; 2024 May; 22(1):249. PubMed ID: 38693584
[TBL] [Abstract][Full Text] [Related]
13. Copper homeostasis and cuproptosis in gynecological disorders: Pathogenic insights and therapeutic implications.
Lin Y; Yuan M; Wang G
J Trace Elem Med Biol; 2024 Jul; 84():127436. PubMed ID: 38547725
[TBL] [Abstract][Full Text] [Related]
14. Cuproptosis Induced by ROS Responsive Nanoparticles with Elesclomol and Copper Combined with αPD-L1 for Enhanced Cancer Immunotherapy.
Guo B; Yang F; Zhang L; Zhao Q; Wang W; Yin L; Chen D; Wang M; Han S; Xiao H; Xing N
Adv Mater; 2023 Jun; 35(22):e2212267. PubMed ID: 36916030
[TBL] [Abstract][Full Text] [Related]
15. Cuproptosis in cancers: Function and implications from bench to bedside.
Huang XY; Shen JY; Huang K; Wang L; Sethi G; Ma Z
Biomed Pharmacother; 2024 Jul; 176():116874. PubMed ID: 38850661
[TBL] [Abstract][Full Text] [Related]
16. Enzalutamide Sensitizes Castration-Resistant Prostate Cancer to Copper-Mediated Cell Death.
Gao X; Zhao H; Liu J; Wang M; Dai Z; Hao W; Wang Y; Wang X; Zhang M; Liu P; Cheng H; Liu Z
Adv Sci (Weinh); 2024 Jun; ():e2401396. PubMed ID: 38859590
[TBL] [Abstract][Full Text] [Related]
17. Copper Homeostasis Based on Cuproptosis-Related Signature Optimizes Molecular Subtyping and Treatment of Glioma.
Zhang S; Yu H; Sun S; Fan X; Bi W; Li S; Wang W; Fang Z; Chen X
Mol Neurobiol; 2023 Dec; ():. PubMed ID: 38151613
[TBL] [Abstract][Full Text] [Related]
18. The molecular mechanisms of cuproptosis and its relevance to cardiovascular disease.
Wang D; Tian Z; Zhang P; Zhen L; Meng Q; Sun B; Xu X; Jia T; Li S
Biomed Pharmacother; 2023 Jul; 163():114830. PubMed ID: 37150036
[TBL] [Abstract][Full Text] [Related]
19. Cuproptosis, the novel therapeutic mechanism for heart failure: a narrative review.
Yuan HJ; Xue YT; Liu Y
Cardiovasc Diagn Ther; 2022 Oct; 12(5):681-692. PubMed ID: 36329965
[TBL] [Abstract][Full Text] [Related]
20. Copper homeostasis and cuproptosis in health and disease.
Chen L; Min J; Wang F
Signal Transduct Target Ther; 2022 Nov; 7(1):378. PubMed ID: 36414625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]